Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. AZN
3. NVDA
4. SPY
5. SATL
6. SRRK
7. LYNX
8. DFTX
9. USO
10. BBNX

Go back to Priovant Announces First Patients Enrolled in Phase 3 Study (BEACON+) of Brepocitinib in Cutaneous Sarcoidosis (CS)
(NASDAQ: ROIV) Delayed: 40.82 --0 (-0%)
Previous Close $40.82    52 Week High $ 
Open $40.82    52 Week Low $ 
Day High $40.82    P/E N/A 
Day Low $40.82    EPS $ 
Volume 160,682